SAN DIEGO, CA, March 17, 2026
Voro Therapeutics has announced a research collaboration with Daiichi Sankyo to advance its PrimeBody™ platform for the development of next-generation tumor-activated antibody-drug conjugates (ADCs), marking a significant step forward in improving the precision, safety, and therapeutic index of targeted cancer therapies. The collaboration will focus on leveraging Voro’s proprietary masking technology to create ADC candidates that remain inactive in healthy tissues and are selectively activated within the tumor microenvironment, addressing key limitations in current oncology treatments.
PrimeBody Platform Enables Tumor-Selective Activation
At the core of the collaboration is Voro’s PrimeBody™ platform, a novel approach designed to mask biologic therapies in circulation and activate them only in tumor tissues, thereby minimizing off-target toxicity. This technology incorporates protease-cleavable linkers and proprietary masking domains, allowing ADCs to remain inactive until they encounter tumor-specific protease activity, where they are then selectively activated.
This mechanism is expected to significantly expand the therapeutic index of ADCs, enabling the use of more potent payloads while reducing systemic side effects. By overcoming one of the major challenges in ADC development—balancing efficacy with safety—the PrimeBody platform has the potential to unlock new therapeutic targets that were previously considered too broadly expressed to be safely targeted.
The collaboration will apply this technology to design and characterize masked ADC candidates against selected oncology targets, combining Voro’s innovation in tumor-activated biologics with Daiichi Sankyo’s global expertise in ADC development and commercialization.
Advertisement
Strategic Collaboration Strengthens Oncology Innovation
Daiichi Sankyo is widely recognized as a leader in antibody-drug conjugate innovation, with a strong track record of developing transformative oncology therapies. This partnership allows both companies to combine complementary strengths, accelerating the development of next-generation targeted treatments.
Under the agreement, Voro will utilize its platform to generate ADC candidates, while benefiting from Daiichi Sankyo’s experience in clinical development, regulatory strategy, and global drug commercialization. This collaboration reflects a growing trend in the biopharmaceutical industry, where strategic partnerships are critical for advancing complex therapeutic technologies and bringing innovative treatments to patients faster.
Additionally, Voro’s prior success with its tumor-activated CD47 blocker program, which has demonstrated improved therapeutic index in preclinical studies, provides a strong foundation for expanding its platform into ADC applications.
Advancing Precision Oncology and Next-Generation Therapeutics
The development of tumor-activated ADCs represents a major advancement in precision oncology, aiming to deliver highly targeted therapies that maximize tumor cell killing while sparing healthy tissues. Traditional ADCs, while effective, often face challenges related to off-target toxicity and limited therapeutic windows, which can restrict their clinical utility.
By introducing tumor-selective activation mechanisms, the PrimeBody platform addresses these challenges, enabling more precise delivery of cytotoxic agents and potentially improving patient outcomes. The ability to control when and where a drug is activated is a key innovation that could redefine the next generation of biologic therapies, including ADCs, T-cell engagers, and cytokine-based treatments.
As oncology continues to evolve toward more personalized and targeted approaches, technologies like PrimeBody are expected to play a central role in enhancing treatment efficacy and safety, supporting the broader goal of improving survival and quality of life for cancer patients.
The collaboration between Voro Therapeutics and Daiichi Sankyo to advance tumor-activated ADCs using the PrimeBody™ platform represents a significant step in next-generation cancer therapy development, combining cutting-edge technology with global pharmaceutical expertise. By focusing on precision targeting, improved therapeutic index, and reduced toxicity, this partnership has the potential to drive meaningful innovation in oncology. For the cGxP.wire audience, this development highlights the importance of biopharmaceutical collaboration, platform technologies, and advanced drug design strategies in shaping the future of cancer treatment.
Source: voro therapeutics, daiichi sankyo press release
